Biotechnology startup Ventus Therapeutics is licensing its lead research program, a drug candidate for inflammatory disorders, to Novo Nordisk in exchange for $70 million.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,